We 100% disagree with Barron’s that General Electric’s deal to sell its BioPharma business to Danaher (tkr: DHR), for $21.4 billion (original deal announced February 2019), should close soon. This is precisely the type of large deal struck at a peak market that will either get delayed indefinitely or negotiated down. Danaher has the upper hand in negotiations as they do not necessarily need to complete this deal. General Electric (tkr: GE) may be facing a cash crunch and is a motivated Seller. Stay tuned.

Related TEK2day article: https://tek2day.com/2020/03/18/ges-biopharma-deal-is-at-risk/